MINNETONKA, Minn. – UnitedHealthcare is partnering with DexCom, a provider of continuous glucose monitoring solutions for diabetes management, on an individualized glucose management pilot program driven by wearable technology to help people with Type 2 diabetes manage their condition in real time. Eligible UnitedHealthcare Medicare Advantage plan participants can use the Dexcom mobile continuous glucose monitoring system to track their blood glucose levels around the clock, as well as access personalized diabetes coaching and an activity tracker to help them understand and act upon the data gathered by the CGM device. “Continuous glucose monitoring can be a game changer for people enrolled in our Medicare Advantage plans, as the data can be translated into personalized information that can be acted upon in real time,” said Brian Thompson, CEO of United Healthcare Medicare & Retirement, in a statement. Dexcom’s technology consists of a sensor that reads glucose levels just beneath the skin. A transmitter sends the data to a smartphone, which processes and displays updated data every five minutes. “The insights that CGM and this program provide can drive significant value to both patients and care providers in helping to better manage diabetes,” said Steve Pacelli, executive vice president of strategy and corporate development at Dexcom, in a statement.
MILPITAS, Calif. – Bigfoot Biomedical plans to conduct a clinical trial of its automated insulin delivery system at sites across the U.S. in 2018, and is looking to expand into Europe and China.
The company signed an agreement earlier this year with Abbott to integrate its FreeStyle Libre glucose sensing technology into the automated insulin delivery system, which does not require fingerstick calibration of a glucose sensor.
“Abbott developed the best, most user-friendly, cost-effective, scalable glucose monitoring technology,” said Jeffrey Brewer, president and CEO of Bigfoot Biomedical, in a feature on the Digital Health Today podcast. “We’re going to build a whole product around it.”
Details of the trial have not yet been announced but Brewer said that, pending approval from the U.S. Food and Drug Administration for the system, a commercial launch is planned for 2020.
As Bigfoot Biomedical moves closer to the trial, Brewer said the pieces are in place for the final assembly of two Class III systems: an artificial intelligence-driven system that uses the interface of a smartphone; and a parallel system that will connect to insulin pens to automate injections. The innovation will ultimately benefit patients, health care providers and insurers, as the data gathered from the system proves its effectiveness.
“You’re doing something with the data that will tie it back to health care economic outcomes that are not only going to drive reimbursement decisions, but make the payers active advocates for the penetration of the technology because it actually saves them money,” he said. “That’s the future of health care.”
SAN DIEGO – People with Type 2 diabetes benefit from the use of continuous glucose monitoring, according to a study published recently in the Annals of Internal Medicine by DexCom, a company that makes a CGM system. Participants in the study achieved significant A1C reduction and spent more time in range, regardless of age, education or math ability. “The results allow us to confidently tell people with Type 2 diabetes using insulin they can use CGM to take control of their disease and make better treatment decisions,” said Dr. Roy Beck, lead study investigator from the Jaeb Center for Health Research, in a statement.
BOSTON – DarioHealth recently announced $5.1 million in aggregate funding. “With this funding, we will accelerate adoption of our innovative and user-friendly remote glucose monitor platform across current markets and also expand into new geographies, such as Germany, in 2017,” said Erez Raphale, DarioHealth chairman and CEO, in a statement. The company will use the funding to promote the platform and further penetrate U.S. and other markets, as well as provide working capital and other general purposes.
NEW YORK – One Drop has received clearance from the U.S. Food and Drug Administration, as well as CE Mark approval, for the One Drop/Chrome, a blood glucose monitoring system.
“One Drop is designed by people with diabetes for people with diabetes, and One Drop/Chrome is a perfect embodiment of our vision,” said Jeff Dachis, One Drop CEO and founder, in a statement.
One Drop/Chrome is available as part of One Drop/Premium, the first monthly subscription service to provide affordable, accessible diabetes care, unlimited blood glucose testing supplies and 24/7 live in-app support.
With One Drop/Mobile’s seamless user experience and deep data integration, users have contributed more than 100 million health data points, logging in more than 2 million times to the app, which tracks blood glucose, medication, food and physical activity.
A recent analysis of data showed that users: consistently tracked their food and blood glucose over time; increased their average number of in-range blood glucose readings by 40%; reduced their average percentage of high blood glucose readings from 18.5% to 3.7%; and reduced their average blood glucose value from 185 mg/dL to 158 mg/dL.
“We’re transforming the diabetes management experience by designing empowering, beautiful products people love to use while also delivering outstanding evidence-based results,” said Dachis.
SUNNYVALE, Calif. – Intuity Medical Inc. has closed a $40 million Series 3 round of funding to launch its POGO Automatic blood glucose monitoring system. “With this recent funding, we have the ability to bring POGO Automatic to the U.S. market for patients who have been looking for a convenient way to test their glucose,” said Emory Anderson, Intuity president and CEO, in a statement. The POGO system combines lancing, blood collection and analysis in one step. Combined with the company’s cloud-based Patterns Diabetes Management System, health care professionals and patients can share a platform for managing glucose information. POGO received clearance from the U.S. Food and Drug Administration in April.
CAMBRIDGE, Mass. – Common Sensing, partnering with Sanofi and Dexom at the Joslin Diabetes Center in Boston, has kicked off a study of its Gocap insulin pen cap. The Gocap is a Bluetooth-enabled insulin-monitoring device that fits on existing disposable injectors and automatically generates an insulin logbook that can be wirelessly shared with care providers and family. Users can see and share their data over the cloud, and receive reminders and alerts from the accompanying Gocap mobile app. The study will look at the use of disposable insulin pens with the smart cap and associated glycemic control. Both insulin pen use and continuous blood glucose response will be measured automatically around the clock for 125 participants.